CSIMarket
 


Catalent Inc   (CTLT)
Other Ticker:  
 

Catalent Inc 's Quick Ratio

CTLT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Catalent Inc 's Cash & cash equivalent grew by 9.57 % in the II Quarter 2023 sequentially, while Current Liabilities decreased, this led to improvement in Catalent Inc 's Quick Ratio to 0.22, Quick Ratio remained below Catalent Inc average.

Within Major Pharmaceutical Preparations industry 92 other companies have achieved higher Quick Ratio than Catalent Inc in second quarter 2023. While Quick Ratio total ranking has improved so far during the II Quarter 2023 to 1310, from total ranking in the first quarter 2023 at 3637.

Explain Quick Ratio?
How much Cash & cash equivalents CTLT´s has?
What are CTLT´s Current Liabilities?


CTLT Quick Ratio (Dec 31 2023)
II. Quarter
(Sep 30 2023)
I. Quarter
(Jun 30 2023)
IV. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
II. Quarter
Y / Y Current Liabilities Change -32.11 % 62.67 % 39.34 % 42.16 % 39.23 %
Y / Y Cash & cash equivalent Change -51.28 % -39.42 % -47.96 % -71.36 % -76.72 %
Quick Ratio MRQ 0.22 0.14 0.18 0.17 0.31
CTLT's Total Ranking # 1310 # 3637 # 0 # 4679 # 349
Seq. Current Liabilities Change -32.46 % 0.26 % 2.89 % -2.56 % 61.82 %
Seq. Cash & cash equivalent Change 9.57 % -25.36 % 11.11 % -46.38 % 36.23 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 93
Healthcare Sector # 222
Overall Market # 1310


Quick Ratio Statistics
High Average Low
1.84 0.55 0.14
(Sep 30 2021)   (Sep 30 2023)




Financial Statements
Catalent Inc 's Current Liabilities $ 1,036 Millions Visit CTLT's Balance sheet
Catalent Inc 's Cash & cash equivalent $ 229 Millions Visit CTLT's Balance sheet
Source of CTLT's Sales Visit CTLT's Sales by Geography


Cumulative Catalent Inc 's Quick Ratio

CTLT's Quick Ratio for the trailling 12 Months

CTLT Quick Ratio

(Dec 31 2023)
II. Quarter
(Sep 30 2023)
I. Quarter
(Jun 30 2023)
IV. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
II. Quarter
Y / Y Current Liabilities TTM Growth -32.11 % 62.67 % 39.34 % 42.16 % 39.23 %
Y / Y Cash & cash equivalent TTM Growth -51.28 % -39.42 % -47.96 % -71.36 % -76.72 %
Quick Ratio TTM 0.17 0.2 0.25 0.32 0.48
Total Ranking TTM # 1765 # 2719 # 2730 # 2710 # 2772
Seq. Current Liabilities TTM Growth -32.46 % 0.26 % 2.89 % -2.56 % 61.82 %
Seq. Cash & cash equivalent TTM Growth 9.57 % -25.36 % 11.11 % -46.38 % 36.23 %


On the trailing twelve months basis In spite of the year on year decrease in CTLT's Current Liabilities to $1,036.00 millions, cumulative Quick Ratio to 0.17 below the CTLT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 221 other companies have achieved higher Quick Ratio than Catalent Inc . While Quick Ratio overall ranking has improved so far to 379, from total ranking during the twelve months ending first quarter 2023 at 4091.

Explain Quick Ratio?
How much Cash & cash equivalents CTLT´s has?
What are CTLT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 222
Healthcare Sector # 500
Within the Market # 1310


trailing twelve months Quick Ratio Statistics
High Average Low
1.11 0.62 0.17
(Dec 31 2021)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Morphosys Ag  0.60 $ 177.520  Millions$ 296.027  Millions
Bio path Holdings inc   0.55 $ 1.052  Millions$ 1.906  Millions
Bristol myers Squibb Company  0.55 $ 12,280.000  Millions$ 22,262.000  Millions
Alimera Sciences Inc   0.55 $ 12.058  Millions$ 21.913  Millions
Teva Pharmaceutical Industries Limited  0.54 $ 3,226.000  Millions$ 5,941.000  Millions
Esperion Therapeutics inc   0.53 $ 82.248  Millions$ 156.224  Millions
Novartis Ag  0.52 $ 13,819.000  Millions$ 26,390.000  Millions
Prestige Consumer Healthcare Inc   0.50 $ 63.615  Millions$ 127.437  Millions
Protokinetix Incorporated  0.46 $ 0.020  Millions$ 0.045  Millions
Akebia Therapeutics Inc   0.43 $ 42.925  Millions$ 99.870  Millions
Entrada Therapeutics Inc   0.43 $ 67.602  Millions$ 158.796  Millions
Optinose Inc   0.42 $ 73.684  Millions$ 176.524  Millions
Elanco Animal Health Inc  0.40 $ 352.000  Millions$ 874.000  Millions
Abbvie inc   0.34 $ 12,816.000  Millions$ 37,841.000  Millions
Ensysce Biosciences Inc   0.34 $ 1.124  Millions$ 3.333  Millions
Ironwood Pharmaceuticals inc   0.33 $ 92.154  Millions$ 276.101  Millions
Aytu Biopharma Inc   0.30 $ 19.529  Millions$ 64.187  Millions
Elite Pharmaceuticals Inc   0.30 $ 5.823  Millions$ 19.159  Millions
Intelgenx Technologies Corp   0.28 $ 2.357  Millions$ 8.423  Millions
Merck and Co Inc   0.28 $ 7,093.000  Millions$ 25,694.000  Millions
Checkpoint Therapeutics Inc   0.27 $ 4.928  Millions$ 18.425  Millions
Pfizer Inc  0.27 $ 12,690.000  Millions$ 47,794.000  Millions
Earth Science Tech Inc   0.25 $ 0.206  Millions$ 0.825  Millions
Organon and Co   0.24 $ 693.000  Millions$ 2,918.000  Millions
Catalent Inc   0.22 $ 229.000  Millions$ 1,036.000  Millions
Bausch Health Companies Inc   0.22 $ 947.000  Millions$ 4,302.000  Millions
Emergent Biosolutions Inc   0.17 $ 111.700  Millions$ 651.300  Millions
Biolinerx Ltd   0.14 $ 4.255  Millions$ 30.852  Millions
Viatris Inc   0.13 $ 991.900  Millions$ 7,777.400  Millions
Integrated Biopharma Inc  0.13 $ 0.732  Millions$ 5.833  Millions

Date modified: 2024-02-15T15:54:19+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com